Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
Galectin Therapeutics announced a major regulatory milestone, reaching an agreement with the FDA on the key elements of the planned Phase 3 trial for belapectin in MASH cirrhosis and portal hypertension, with a protocol submission expected in Q3 2026. The company significantly strengthened its balance sheet by converting approximately $105.8 million of debt and accrued interest from Chairman Richard E. Uihlein into 34.4 million shares of common stock, eliminating the liability.
Key figures
- Net loss
- $9.2 million
- Ga expenses
- $1.8 million
- Rd expenses
- $2.1 million
- Cash position
- $13.2 million
- Debt eliminated
- $105.8 million
- Shares issued conversion
- 34,376,167
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.